ACET stock gains on new early-stage data for CAR-T therapy in blood cancer (NASDAQ:ACET)
seekingalpha.com
finance
2022-05-27 10:43:42

libre de droit/iStock via Getty Images Adicet Bio (NASDAQ:ACET) has added ~11% in the pre-market Friday after the clinical-stage biotech announced additional Phase 1 data for its chimeric antigen receptor (CAR) T cell therapy ADI-001 in relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL). Results as of Feb. 14, 2021, data-cut date were made available in an abstract ahead of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting next week. Highlights of the release include a 67% overall response rate (ORR) and the complete response (CR) out of six evaluable patients on Day 28 who received two doses of ADI-001: 30 million CAR+ cells and 100 million CAR+ cells.
